相似文献
1
Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
Br J Cancer. 1998;77(2):216-20. doi: 10.1038/bjc.1998.36.
2
Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
Br J Cancer. 1994 Oct;70(4):573-8. doi: 10.1038/bjc.1994.353.
3
4
Structural modifications of bryostatin 2.
Anticancer Drug Des. 1992 Apr;7(2):101-14.
5
Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
Leuk Res. 1995 Sep;19(9):667-73. doi: 10.1016/0145-2126(95)00037-o.
6
7
Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Cancer Res. 1992 Jun 1;52(11):3119-24.
8
Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Leuk Lymphoma. 1993 Jan;9(1-2):141-8. doi: 10.3109/10428199309148517.
9
Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation.
Eur J Immunol. 1990 Jan;20(1):119-27. doi: 10.1002/eji.1830200118.
引用本文的文献
1
Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation.
Int J Mol Sci. 2025 Aug 11;26(16):7765. doi: 10.3390/ijms26167765.
2
The Novel PKCθ from Benchtop to Clinic.
J Immunol Res. 2015;2015:348798. doi: 10.1155/2015/348798. Epub 2015 May 19.
3
The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
BMC Cancer. 2015 Jun 19;15:474. doi: 10.1186/s12885-015-1445-0.
4
Bryostatin-1 causes radiosensitization of BMG-1 malignant glioma cells through differential activation of protein kinase-Cδ not evident in the non-malignant AA8 fibroblasts.
Mol Cell Biochem. 2015 Mar;401(1-2):49-59. doi: 10.1007/s11010-014-2291-0. Epub 2014 Dec 4.
5
Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer.
Invest New Drugs. 2001;19(3):249-54. doi: 10.1023/a:1010628903248.
6
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
Br J Cancer. 2001 Feb;84(4):465-9. doi: 10.1054/bjoc.2000.1624.
本文引用的文献
1
A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
Br J Cancer. 1993 Aug;68(2):418-24. doi: 10.1038/bjc.1993.352.
2
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
J Natl Cancer Inst. 1993 Nov 17;85(22):1812-8. doi: 10.1093/jnci/85.22.1812.
3
Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
Br J Cancer. 1994 Oct;70(4):573-8. doi: 10.1038/bjc.1994.353.
4
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
J Clin Oncol. 1993 Oct;11(10):1957-68. doi: 10.1200/JCO.1993.11.10.1957.
5
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Br J Cancer. 1995 Aug;72(2):461-8. doi: 10.1038/bjc.1995.356.
6
Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.
Carcinogenesis. 1987 Sep;8(9):1343-6. doi: 10.1093/carcin/8.9.1343.
7
Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue.
Cancer Res. 1988 Jul 1;48(13):3626-9.
8
Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor.
Biochem Biophys Res Commun. 1985 Sep 30;131(3):1109-16. doi: 10.1016/0006-291x(85)90205-0.
9
Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells.
Int J Cancer. 1989 Jan 15;43(1):158-63. doi: 10.1002/ijc.2910430129.
10
Zotero 插件